For most fields of medicine, new drugs (and not reiterations of previously-approved drugs) are rare. Further, a new drug will have generated extensive hype before its approval, given the requirement for Phase I, II and III trials for most approvals.<p>I don&#x27;t think it&#x27;s at all unreasonable to state that physicians are more than able to track all drugs relevant to their core patient populations.